APA (7th ed.) Citation

Dietrich, S., Schönland, S., Benner, A., Bochtler, T., Kristen, A., Beimler, J., . . . Hegenbart, U. (2010). Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement. Blood, 116(4), . https://doi.org/10.1182/blood-2009-11-253237

Chicago Style (17th ed.) Citation

Dietrich, Sascha, et al. "Treatment with Intravenous Melphalan and Dexamethasone Is Not Able to Overcome the Poor Prognosis of Patients with Newly Diagnosed Systemic Light Chain Amyloidosis and Severe Cardiac Involvement." Blood 116, no. 4 (2010). https://doi.org/10.1182/blood-2009-11-253237.

MLA (9th ed.) Citation

Dietrich, Sascha, et al. "Treatment with Intravenous Melphalan and Dexamethasone Is Not Able to Overcome the Poor Prognosis of Patients with Newly Diagnosed Systemic Light Chain Amyloidosis and Severe Cardiac Involvement." Blood, vol. 116, no. 4, 2010, https://doi.org/10.1182/blood-2009-11-253237.